贝林妥欧单抗联合化疗个体化治疗婴儿白血病的病例报道  

A case of individualized treatment of blinatumomab combined with chemotherapy for infant leukemia

作　　者：史校东 罗丹 沙莎 刘燕 曹静 吴丹[1] SHI Xiaodong;LUO Dan;SHA Sha;LIU Yan;CAO Jing;WU Dan(Department of Pharmacy,Baoding Hospital of Beijing Children's Hospital,Capital Medical University,Baoding,071000,Hebei,China;Hematologic Oncology Department/Hebei Key Laboratory of Infectious Diseases Pathogenesis and Precise Diagnosis and Treatment/Baoding Key Laboratory of Pediatric Hematology Oncology,Baoding Hospital of Beijing Children's Hospital,Capital Medical University,Baoding,071000,Hebei,China)

机构地区：[1]首都医科大学附属北京儿童医院保定医院药剂科/河北省儿童感染性疾病发病机制及精准诊治研究重点实验室/保定市儿童血液病与肿瘤精准诊治研究实验室,河北保定071000 [2]首都医科大学附属北京儿童医院保定医院血液肿瘤科/河北省儿童感染性疾病发病机制及精准诊治研究重点实验室/保定市儿童血液病与肿瘤精准诊治研究实验室,河北保定071000

出　　处：《肿瘤药学》2024年第5期645-648,共4页Anti-Tumor Pharmacy

基　　金：保定市科技计划项目(2441ZF139)。

摘　　要：目的分析1例婴儿急性B淋巴细胞白血病(B-ALL)的病例,探讨贝林妥欧单抗治疗婴儿白血病的安全性及有效性。方法回顾性分析1例婴儿B-ALL的个体化治疗方案,并结合文献复习,监测贝林妥欧单抗的安全性和有效性。结果婴儿诱导化疗后微小残留病灶(MRD)阳性且不耐受强化疗,调整为贝林妥欧单抗联合低剂量化疗、去甲基化药物个体化治疗,MRD转阴且持续阴性,未发生严重不良反应。结论贝林妥欧单抗联合低剂量化疗、去甲基化药物个体化治疗婴儿白血病疗效显著,且安全性良好。Objective To analyze a case of infant B-acute lymphoblastic leukemia(B-ALL),and to explore the safety and efficacy of blinatumomab in the treatment of infant B-ALL.Methods The individualized treatment of an infant with B-ALL was retrospectively analyzed,and the safety and efficacy of blinatumomab were monitored in combination with litera-ture review.Results After induction chemotherapy,the infant had a positive minimum residual disease(MRD)and was in-tolerant to intensive chemotherapy.Then the infant was given individualized treatment adjusted as blinatumomab combined with low-dose chemotherapy and hypomethylating drugs.His MRD become negative and continued to be negative.No seri-ous adverse reactions occurred.Conclusion Blinatumomab combined with low-dose chemotherapy and hypomethylating drugs has significant efficacy and good safety in the individualized treatment of infant leukemia.

关 键 词：婴儿白血病 贝林妥欧单抗 联合化疗 个体化治疗 病例报道 

分 类 号：R733.7[医药卫生—肿瘤] R725.5[医药卫生—临床医学]